Jasper Therapeutics(JSPR) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended ...